MARKET

AKRO

AKRO

Akero
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.14
+0.34
+1.30%
Opening 14:00 10/22 EDT
OPEN
25.67
PREV CLOSE
25.80
HIGH
26.49
LOW
25.67
VOLUME
60.51K
TURNOVER
--
52 WEEK HIGH
41.16
52 WEEK LOW
10.78
MARKET CAP
906.90M
P/E (TTM)
-12.5276
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Akero Therapeutics To Present At Upcoming Conferences In November
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present at the following investor conferences next month:
PR Newswire · 20h ago
Akero Therapeutics TO Present At Credit Suisse Healthcare Conference On Nov. 9, Jeffries Global Healthcare Conference On Nov. 17
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with
Benzinga · 21h ago
A Look Into Healthcare Sector Value Stocks
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: 1. Oncternal Therapeutics (NASDAQ: ONCT) - P/E: 1.98 2. Morphic Holding (NASDAQ: MORF) - P/E: 7.29 3. Akero Therapeutics (NASDAQ: AKRO) - P/E: 8.31 4. Sanofi (NASDAQ: SNY) - P/E: 9.67 5. Xenetic Biosciences (NASDAQ: XBIO) - P/E: 0.8Most recently, Oncternal Therapeutics reported earnings per share at -0.34, whereas in Q1 earnings per share sat at -0.31. Oncternal Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Morphic Holding's earnings per share for Q2 sits at -0.52, whereas in Q1, they were at -0.55. Morphic Holding does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Akero Therapeutics reported earnings per share at -0.57, whereas in Q1 earnings per share sat at -0.42. Akero Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Sanofi's earnings per share for Q2 sits at 1.41, whereas in Q1, they were at 1.8. Sanofi does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Xenetic Biosciences saw an increase in earnings per share from -0.19 in Q1 to -0.15 now. Xenetic Biosciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * ManpowerGroup's Earnings Outlook * Preview: Mercantile Bank's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 3d ago
EMA grants PRIME designation to Akero Therapeutics' efruxifermin
The European Medicines Agency ((EMA)) has granted Priority Medicines ((PRIME)) designation to Akero Therapeutics' (AKRO) efruxifermin ((EFX)), an investigational FGF21 analog for the treatment of non-alcoholic steatohepatitis ((NASH)).PRIME, akin to
Seekingalpha · 6d ago
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to efruxifermin (EFX), an investigational FGF21 analog for the treatment of NASH. The designation was granted based on the positive efficacy data recently reported from the company's Phase 2a BALANCED study. Based on available published data, EFX is believed to be the first drug candidate to receive a PRIME designation for treatment of NASH.
PR Newswire · 6d ago
Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting 2020 Nov. 13-16
SOUTH SAN FRANCISCO,Calif., Oct. 2, 2020 /PRNewswire/ -- Akero Therapeutics,Inc.(NASDAQ:AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed torestore
Benzinga · 10/02 11:31
Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
PR Newswire · 09/28 21:05
Akero to evaluate lead asset in an adaptive Phase 2b/3 NASH trial
Akero Therapeutics (AKRO) has received written guidance from the FDA that enables the company to implement a combined Phase 2b/3 study for its lead candidate efruxifermin ((EFX)) in NASH patients.Under the planned
Seekingalpha · 09/24 12:49
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKRO. Analyze the recent business situations of Akero through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKRO stock price target is 60.00 with a high estimate of 79.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 22.16M
% Owned: 63.86%
Shares Outstanding: 34.70M
TypeInstitutionsShares
Increased
33
1.49M
New
28
-133.96K
Decreased
18
1.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.30%
Pharmaceuticals & Medical Research
+0.27%
Key Executives
Non-Executive Chairman/Independent Director
Mark Iwicki
President/Chief Executive Officer/Director
Andrew Cheng
Co-Founder/Chief Operating Officer/Executive Vice President
Jonathan Young
Co-Founder/Chief Scientific Officer
Timothy Rolph
Chief Financial Officer/Executive Vice President
William White
Other
Kitty Yale
Independent Director
Tomas Heyman
Non-Executive Independent Director
Kevin Bitterman
Non-Executive Independent Director
Seth Harrison
Non-Executive Independent Director
Jane Henderson
Non-Executive Independent Director
Graham Walmsley
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AKRO
Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. Its lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, with the potential to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Akero Therapeutics Inc stock information, including NASDAQ:AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.